K2 Medical Research, LLC
K2 Medical Research, LLC
Maitland, Florida, United States10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-09 | NCT07177352 | |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-09-25 | NCT07169578 | |
| Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT04639050 | |
| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-10 | NCT07717411 | |
| An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease | Alzheimer s Disease | Recruiting | Phase 1 | 2026-09-04 | NCT07764146 | |
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Frontotemporal Lobar Degeneration, Pick disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 | 2026-08-24 | NCT06297590 | |
| Alzheimer's Plasma Extension | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Enrolling by invitation | Not stated | 2026-08-18 | NCT06416072 | |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-08-10 | NCT05531656 | |
| AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | Early Preclinical Alzheimer's Disease; Preclinical Alzheimer's Disease | Active, not recruiting | Phase 3 | 2026-06-04 | NCT04468659 | |
| A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 | 2026-04-20 | NCT06809400 |